22 citations
,
November 2011 in “Journal of Analytical Toxicology” Scientists have developed a new method to detect steroid abuse in athletes using cell-based tests, which could be the future of anti-doping methods.
January 2018 in “Journal of the American Academy of Dermatology” More extensive trials are needed to understand tofacitinib's role in treating severe hair loss.
July 2025 in “Clinical Case Reports” A new genetic mutation in the TRPS1 gene causes Trichorhinophalangeal Syndrome, leading to specific hair, dental, and bone issues.
3 citations
,
May 2025 in “Carbohydrate Polymers” The new microneedle patch effectively treats alopecia areata with fewer side effects than oral medication.
December 2025 in “Cureus” Hyperbaric oxygen therapy speeds up recovery and improves outcomes in hair transplants.
3 citations
,
August 2013 in “International journal of research in Ayurveda and pharmacy” Hairbac tablet and oil significantly improve hair texture, density, and reduce hair loss without side effects.
2 citations
,
January 2023 in “Anais Brasileiros de Dermatologia”
April 2016 in “Journal of The American Academy of Dermatology” The study found that Temporal Triangular Alopecia often starts in early childhood, mainly affects the left side of the scalp, and has no effective treatment except surgery.
12 citations
,
January 2001 in “Der Hautarzt” Trichorhinophalangeal syndrome causes hair, facial, and bone issues, with no specific treatment beyond gentle care.
1 citations
,
July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.
Botulinum toxin injections do not help with male pattern baldness.
8 citations
,
January 2023 in “Indian Dermatology Online Journal” Baricitinib effectively treats certain skin conditions but may have serious side effects.
May 2024 in “Journal of cosmetic dermatology” Tofacitinib is an effective and safe treatment for alopecia areata.
77 citations
,
January 1980 in “Carcinogenesis” TPA is about 50 times more effective at promoting tumors than MZ.
2 citations
,
June 2025 in “Drug Testing and Analysis” The method effectively detects MeT and TP in dried blood spots after cream application.
October 2022 in “Amplla Editora eBooks” Traumatic brain injury hospitalizations in Brazil showed specific trends and patterns from 2008 to 2021.
January 2022 in “International review of movement disorders” Cannabinoid and steroid-based drugs could be new treatments for Tourette syndrome, but more research is needed to confirm their effectiveness and safety.
December 2024 in “Clinical and Experimental Dermatology” Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.
Thymosin β4 helps with healing, inflammation, and organ protection.
1 citations
,
January 2022 in “Annals of Dermatology” A new mutation in the MBTPS2 gene causes a mild form of IFAP syndrome.
17 citations
,
October 2023 in “Polymers” Electrospun nanofibers are promising for medical, sensing, and energy uses, especially with 3D printing.
65 citations
,
February 2015 in “Neuro-Oncology” Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.
5 citations
,
May 2011 in “Movement Disorders” Finasteride significantly reduced tics and obsessive-compulsive symptoms in Tourette syndrome patients.
October 2024 in “International Journal of Research in Dermatology” Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
July 2020 in “Benha Medical Journal” People with severe Alopecia Areata have higher levels of TGF-β1, which may play a role in the condition.
November 2022 in “Journal of the Endocrine Society” Taking biotin can lead to incorrect low results in free testosterone tests.
December 2023 in “Journal of Science Innovations and Nature of Earth” Tribulus terrestris may protect the liver from drug damage.
June 2024 in “Australasian Journal of Dermatology” Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.
February 2025 in “Canadian Journal of Health Technologies” Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.
Bicalutamide does not significantly affect liver enzymes and is a safe anti-androgen option for transfeminine individuals.